{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:37:42Z","timestamp":1787621862629,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02388-x","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:44:19Z","timestamp":1778906659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Melissa","family":"Istoc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit A.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune H.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar M.","family":"Al-Khazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"033310242412526","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener H-C et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44:03331024241252666","journal-title":"Cephalalgia"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Buse DC, Ashina H et al (2021) Migraine: integrated approaches to clinical management and emerging treatments. Lancet (London England) 397:1505\u20131518","journal-title":"Lancet (London England)"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/head.13588","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Munjal S, Buse DC et al (2019) Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache 59:1310\u20131323","journal-title":"Headache"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1474-4422(24)00003-6","volume":"23","author":"C-C Chiang","year":"2024","unstructured":"Chiang C-C, Porreca F, Robertson CE et al (2024) Potential treatment targets for migraine: emerging options and future prospects. Lancet Neurol 23:313\u2013324","journal-title":"Lancet Neurol"},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U et al (2025) Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet 405:1014\u20131026","journal-title":"Lancet"},{"key":"2388_CR6","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MAM et al (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet (London England) 397:1496\u20131504","journal-title":"Lancet (London England)"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40263-023-00988-8","volume":"37","author":"HA Blair","year":"2023","unstructured":"Blair HA, Rimegepant (2023) A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs 37:255\u2013265","journal-title":"CNS Drugs"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D et al (2014) BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114\u2013125","journal-title":"Cephalalgia"},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG et al (2019) Rimegepant, an Oral Calcitonin Gene\u2013Related Peptide Receptor Antagonist, for Migraine. N Engl J Med 381:142\u2013149","journal-title":"N Engl J Med"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745","journal-title":"Lancet"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/JPR.S453806","volume":"17","author":"R Lipton","year":"2024","unstructured":"Lipton R, Thiry A, Morris B et al (2024) Efficacy and Safety of Rimegepant 75\u00a0mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. JPR 17:2431\u20132441","journal-title":"JPR"},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim B-K, Guo A et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22:476\u2013484","journal-title":"Lancet Neurol"},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1111\/head.14994","volume":"65","author":"K Ikeda","year":"2025","unstructured":"Ikeda K, Matsumori Y, Kudo M et al (2025) Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose-ranging, double\u2010blind, randomized controlled trial. Headache 65:1811\u20131820","journal-title":"Headache"},{"key":"2388_CR14","doi-asserted-by":"publisher","first-page":"033310242513952","DOI":"10.1177\/03331024251395298","volume":"45","author":"M Ashina","year":"2025","unstructured":"Ashina M, McAllister P, Gaul C et al (2025) Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial. Cephalalgia 45:03331024251395298","journal-title":"Cephalalgia"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"H-C Diener","year":"2019","unstructured":"Diener H-C, Tassorelli C, Dodick DW et al (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 39:687\u2013710","journal-title":"Cephalalgia"},{"key":"2388_CR16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006\u20131012","journal-title":"J Clin Epidemiol"},{"key":"2388_CR17","first-page":"1","volume":"8","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"1988","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8:1\u201396","journal-title":"Cephalalgia"},{"key":"2388_CR18","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2004) The International Classification of Headache Disorders, 2nd edition. Cephalalgia 24:1\u2013160"},{"key":"2388_CR19","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia: Int J headache 33:629\u2013808","DOI":"10.1177\/0333102413485658"},{"key":"2388_CR20","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018) ; 38: 1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"2388_CR21","doi-asserted-by":"publisher","unstructured":".Sterne JAC, Savovi\u0107 J, Page MJ (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Res ed); 366. Epub ahead of print https:\/\/doi.org\/10.1136\/BMJ.L4898","DOI":"10.1136\/BMJ.L4898"},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"2388_CR23","doi-asserted-by":"crossref","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA et al (2024) Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ ; e080107","DOI":"10.1136\/bmj-2024-080107"},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-024-01935-8","volume":"26","author":"LF Iannone","year":"2025","unstructured":"Iannone LF, Vaghi G, Sebastianelli G et al (2025) Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain 26:4","journal-title":"J Headache Pain"},{"key":"2388_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17581869.2025.2494494","volume":"15","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Jedie B, Barhum F et al (2025) Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manage 15:279\u2013284","journal-title":"Pain Manage"},{"key":"2388_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-023-00803-4","volume":"19","author":"H Ashina","year":"2023","unstructured":"Ashina H, Tfelt-Hansen P (2023) Zavegepant for the acute treatment of migraine: look before leaping. Nat Rev Neurol 19:329\u2013330","journal-title":"Nat Rev Neurol"},{"key":"2388_CR27","doi-asserted-by":"crossref","unstructured":"Derry S, Moore RA (2013) Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev; 2013: CD008040","DOI":"10.1002\/14651858.CD008614.pub2"},{"key":"2388_CR28","doi-asserted-by":"crossref","unstructured":"Law S, Derry S, Moore RA (2013) Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews; 2013: CD009455","DOI":"10.1002\/14651858.CD009455.pub2"},{"key":"2388_CR29","doi-asserted-by":"crossref","unstructured":"Derry CJ, Derry S, Moore RA (2014) Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev; 2014: CD009108","DOI":"10.1002\/14651858.CD009108.pub2"},{"key":"2388_CR30","doi-asserted-by":"crossref","unstructured":"Bird S, Derry S, Moore RA (2014) Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev; 2014: CD008616","DOI":"10.1002\/14651858.CD008616.pub2"},{"key":"2388_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14737175.2026.2621879","volume":"26","author":"L Pellesi","year":"2026","unstructured":"Pellesi L, Scuteri D, Martelletti P (2026) Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectives. Expert Rev Neurother 26:315\u2013323","journal-title":"Expert Rev Neurother"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/head.70034","volume":"66","author":"L Charleston","year":"2026","unstructured":"Charleston L, Armand CE, Monteith TS et al (2026) Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo-controlled clinical trials. Headache 66:874\u2013884","journal-title":"Headache"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S et al (2021) Diagnosis and management of migraine in ten steps. Nat Reviews Neurol 17:501\u2013514","journal-title":"Nat Reviews Neurol"},{"key":"2388_CR34","doi-asserted-by":"publisher","first-page":"fcag004","DOI":"10.1093\/braincomms\/fcag004","volume":"8","author":"BA Chaudhry","year":"2026","unstructured":"Chaudhry BA, Younis S, Al-Mashat H et al (2026) Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study. Brain Commun 8:fcag004","journal-title":"Brain Commun"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"033310242412329","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D et al (2024) A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia 44:03331024241232944","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02388-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:02:08Z","timestamp":1783566128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02388-x","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BAC has received personal fees from Pfizer, outside of the submitted work. RHC has received personal fees from AbbVie, Lundbeck, Pfizer, and Teva, outside of the submitted work. RHC has also received a travel grant from the Augustinus Foundation. HMA has received personal fees from AbbVie, Lundbeck, and Pfizer, outside of the submitted work. MA has received personal fees from AbbVie, AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva, outside of the submitted work. MA has received institutional research grants from the Danish National Research Foundation, Novartis, Novo Nordisk Foundation, and Lundbeck Foundation. MA is also an Associate Editor of Brain and The Journal of Headache and Pain. WKK has received personal fees from AbbVie, Lundbeck, Pfizer, and Teva, outside of the submitted work. HA has received personal fees from AbbVie, Lundbeck, Pfizer, and Teva, outside the submitted work. HA has received institutional research grants from Lundbeck Foundation. HA is also an Editorial Board Member of The Journal of Headache and Pain. The remaining author reports no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}